| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 1729 | 2014 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 583 | 2016 |
| EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes JJM Van Dongen, L Lhermitte, S Böttcher, J Almeida, VHJ Van der Velden, ... Leukemia 26 (9), 1908, 2012 | 570 | 2012 |
| Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide … MV Mateos, A Oriol, J Martínez-López, N Gutiérrez, AI Teruel, R de Paz, ... The lancet oncology 11 (10), 934-941, 2010 | 485 | 2010 |
| New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis … E Pérez-Persona, MB Vidriales, G Mateo, R García-Sanz, MV Mateos, ... Blood 110 (7), 2586-2592, 2007 | 422 | 2007 |
| KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA … AC Garcia-Montero, M Jara-Acevedo, C Teodosio, ML Sanchez, R Nunez, ... Blood 108 (7), 2366-2372, 2006 | 420 | 2006 |
| EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols T Kalina, J Flores-Montero, VHJ Van Der Velden, M Martin-Ayuso, ... Leukemia 26 (9), 1986, 2012 | 417 | 2012 |
| Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation B Paiva, MB Vidriales, J Cerveró, G Mateo, JJ Pérez, MA Montalbán, ... Blood 112 (10), 4017-4023, 2008 | 379 | 2008 |
| Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma MV Mateos, MT Hernández, P Giraldo, J de la Rubia, F de Arriba, ... New England Journal of Medicine 369 (5), 438-447, 2013 | 351 | 2013 |
| Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma J Martinez-Lopez, JJ Lahuerta, F Pepin, M González, S Barrio, R Ayala, ... Blood 123 (20), 3073-3079, 2014 | 288 | 2014 |
| Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells M Urashima, A Ogata, D Chauhan, M Hatziyanni, MB Vidriales, ... Blood 87 (5), 1928-1938, 1996 | 256 | 1996 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood 119 (3), 687-691, 2012 | 229 | 2012 |
| Human peripheral blood B‐cell compartments: a crossroad in B‐cell traffic M Perez‐Andres, B Paiva, WG Nieto, A Caraux, A Schmitz, J Almeida, ... Cytometry Part B: Clinical Cytometry 78 (S1), S47-S60, 2010 | 225 | 2010 |
| Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138− and CD138+ plasma cells A Caraux, B Klein, B Paiva, C Bret, A Schmitz, GM Fuhler, NA Bos, ... haematologica 95 (6), 1016-1020, 2010 | 221 | 2010 |
| Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma B Paiva, J Martinez-Lopez, MB Vidriales, MV Mateos, MA Montalban, ... J Clin Oncol 29 (12), 1627-1633, 2011 | 214 | 2011 |
| Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy G Mateo, MA Montalbán, MB Vidriales, JJ Lahuerta, MV Mateos, ... Journal of Clinical Oncology 26 (16), 2737-2744, 2008 | 207 | 2008 |
| Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell‐related disorders B Paiva, J Almeida, M Pérez‐Andrés, G Mateo, A López, A Rasillo, ... Cytometry Part B: Clinical Cytometry 78 (4), 239-252, 2010 | 203 | 2010 |
| New criteria for response assessment: role of minimal residual disease in multiple myeloma B Paiva, JJM van Dongen, A Orfao Blood, The Journal of the American Society of Hematology 125 (20), 3059-3068, 2015 | 201 | 2015 |
| Increased frequency (12%) of circulating chronic lymphocytic leukemia–like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach WG Nieto, J Almeida, A Romero, C Teodosio, A López, AF Henriques, ... Blood, The Journal of the American Society of Hematology 114 (1), 33-37, 2009 | 201 | 2009 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, JM Hernandez, ... Leukemia 27 (8), 1722, 2013 | 191 | 2013 |
